Adrian P Mansini (Adrian Mansini)

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 11

Top Topics

Epithelial Mesenchymal Transition

Molecular Dynamics

Ejection Fraction

Top Venues

Research square

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Marina G Ferrari, Alexis P Jimenez-Uribe, Li Wang, Luke H Hoeppner, Paari Murugan, Eunsil Hahm, Jindan Yu, Timothy M Kuzel, Sergio A Gradilone, Adrian P Mansini
Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target. Oncogene (2023)
Marina G Ferrari, Alexis P Jimenez-Uribe, Li Wang, Luke H Hoeppner, Paari Murugan, Eunsil Hahm, Jindan Yu, Timothy M Kuzel, Sergio A Gradilone, Adrian P Mansini
Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target. Oncogene 43 (7) (2023)
Marina G Ferrari, Alexis P Jimenez-Uribe, Li Wang, Luke H Hoeppner, Paari Murugan, Eunsil Hahm, Jindan Yu, Timothy M Kuzel, Sergio A Gradilone, Adrian P Mansini
Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target. Oncogene 43 (7) (2023)
Marina G Ferrari, Alexis P Jimenez-Uribe, Li Wang, Luke H Hoeppner, Paari Murugan, Eunsil Hahm, Jindan Yu, Timothy M Kuzel, Sergio A Gradilone, Adrian P Mansini
Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target. Oncogene 43 (7) (2023)
Marina G Ferrari, Alexis P Jimenez-Uribe, Li Wang, Luke H Hoeppner, Paari Murugan, Eunsil Hahm, Jindan Yu, Timothy M Kuzel, Sergio A Gradilone, Adrian P Mansini
Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target. Oncogene 43 (7) (2023)
Marina G Ferrari, Alexis P Jimenez-Uribe, Li Wang, Luke H Hoeppner, Paari Murugan, Eunsil Hahm, Jindan Yu, Timothy M Kuzel, Sergio A Gradilone, Adrian P Mansini
Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target. Oncogene 43 (7) (2023)
Marina G Ferrari, Alexis P Jimenez-Uribe, Li Wang, Luke H Hoeppner, Paari Murugan, Eunsil Hahm, Jindan Yu, Timothy M Kuzel, Sergio A Gradilone, Adrian P Mansini
Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target. Oncogene (2023)
Marina Ferrari, Li Wang, Luke H Hoeppner, Eunsil Hahm, Jindan Yu, Timothy Kuzel, Adrian P Mansini
Myeloid differentiation factor-2/LY96, a new predictive biomarker of metastasis in prostate cancer: Clinical implications as a potential therapeutic target. Research square (2023)
Marina G Ferrari, Alexis P Jimenez-Uribe, Li Wang, Luke H Hoeppner, Paari Murugan, Eunsil Hahm, Jindan Yu, Timothy M Kuzel, Sergio A Gradilone, Adrian P Mansini
Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target. Oncogene (2023)
Marina G Ferrari, Alexis P Jimenez-Uribe, Li Wang, Luke H Hoeppner, Paari Murugan, Eunsil Hahm, Jindan Yu, Timothy M Kuzel, Sergio A Gradilone, Adrian P Mansini
Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target. Oncogene 43 (7) (2023)
Arsheed A Ganaie, Adrian P Mansini, Tabish Hussain, Arpit Rao, Hifzur R Siddique, Ashraf Shabaneh, Marina G Ferrari, Paari Murugan, Jörg Klingelhöfer, Jinhua Wang, Noona Ambartsumian, Christopher A Warlick, Badrinath R Konety, Mohammad Saleem
Anti-S100A4 Antibody Therapy Is Efficient in Treating Aggressive Prostate Cancer and Reversing Immunosuppression: Serum and Biopsy S100A4 as a Clinical Predictor. Molecular cancer therapeutics 19 (12) (2020)